Bücher der Reihe Cancer Drug Discovery and Development

This book provides insight into established practices and research into apoptosis and senescence. The volume thoroughly examines novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics that still hold mysteries for researchers.

This book provides insight into established practices and research into apoptosis and senescence. The volume thoroughly examines novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics that still hold mysteries for researchers.

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy. The companion volume details the role of TGF- ss on basic and clinical biology.

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy.

While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.

This book presents the first comprehensive exploration of the dynamic potential of microtubules anti-cancer targets. Written by leading anti-cancer researchers, this groundbreaking volume collects the most current microtubule research available and investigates the potential of microtubules in cancer therapy.

The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island).

A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies.

Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond.

DNA topoisomerases represent an essential family of DNA processing enzymes and a large number of topoisomerase inhibitors are used clinically for the treatment of various human cancers.

This book presents an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer.

The book will detail the history, successes, and failures of targeted therapies for cancer, with a particular focus on IGF systems and cancer.

Significance of Stem Cells to Tumor DevelopmentCancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve.

In this volume, Supportive Care in Cancer Therapy, a part of the Cancer Drug Discovery and Development series, the contributors provide an up-to-date, concise review of specific consequences of cancer and its treatment.

Covers topics that range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of the clinical trials underway.

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments.

This book shows how a bioinformatics approach has been used to characterize various cancer-related processes. It provides a historical and technical perspective on the analytical techniques, methodologies, and platforms used in bioinformatics experiments.

Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells.

While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.

Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered.

This monograph will be the first to focus on studies that investigate the role of NO in tumor cell pathogenesis, growth, angiogenesis, response to cytotoxic therapies and NO translational applications in cancer therapy, alone or in conjunction with other therapies.

This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

Significance of Stem Cells to Tumor DevelopmentCancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve.

This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint.

Reviews the role of HGFs in clinical practice, explains the molecular basis of their effects, and considers potential developments. This book focuses on the use of HGFs in oncology, describing their application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, and more.

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.

Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.